BR0115624A - neurotoxinas com especificidade alvo melhorada - Google Patents

neurotoxinas com especificidade alvo melhorada

Info

Publication number
BR0115624A
BR0115624A BRPI0115624-1A BR0115624A BR0115624A BR 0115624 A BR0115624 A BR 0115624A BR 0115624 A BR0115624 A BR 0115624A BR 0115624 A BR0115624 A BR 0115624A
Authority
BR
Brazil
Prior art keywords
neurotoxins
target specificity
enhanced target
proteases
present
Prior art date
Application number
BRPI0115624-1A
Other languages
English (en)
Inventor
Wei-Jen Lin
Kei Roger Aoki
Lance E Steward
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0115624A publication Critical patent/BR0115624A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"NEUROTOXINAS COM ESPECIFICIDADE ALVO MELHORADA". A presente invenção refere-se a neurotoxinas modificadas que contêm sítios de clivagem protease suscetíveis unicamente às proteases presentes em certos tecidos. As toxinas podem ser ativadas seletivamente por protease em músculos ou inativadas seletivamente por proteases no sangue.
BRPI0115624-1A 2000-11-29 2001-11-27 neurotoxinas com especificidade alvo melhorada BR0115624A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/726,949 US7273722B2 (en) 2000-11-29 2000-11-29 Neurotoxins with enhanced target specificity
PCT/US2001/045059 WO2002044199A2 (en) 2000-11-29 2001-11-27 Neurotoxins with enhanced target specificity

Publications (1)

Publication Number Publication Date
BR0115624A true BR0115624A (pt) 2006-02-21

Family

ID=24920702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0115624-1A BR0115624A (pt) 2000-11-29 2001-11-27 neurotoxinas com especificidade alvo melhorada

Country Status (7)

Country Link
US (3) US7273722B2 (pt)
EP (1) EP1381677A2 (pt)
JP (1) JP2005506036A (pt)
AU (1) AU2002228684B9 (pt)
BR (1) BR0115624A (pt)
CA (1) CA2430365A1 (pt)
WO (1) WO2002044199A2 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
AU2005279741B2 (en) * 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
JP2008532549A (ja) * 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
CA2610103A1 (en) * 2005-09-19 2007-03-19 Allergan, Inc. Clostridial toxin activatable clostridial toxins
AU2007272515B2 (en) * 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP2505592A1 (en) 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
US20100278826A1 (en) * 2008-06-10 2010-11-04 Shoemaker Charles B Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US9149666B2 (en) 2009-08-17 2015-10-06 East Carolina University Fast acting SNARE-cleaving enzymes
EP2483666A1 (en) 2009-10-02 2012-08-08 Allergan, Inc. In vitro method of determining changes in a protein environment
US8980284B2 (en) * 2010-01-25 2015-03-17 New York University Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
CN102822196B (zh) 2010-01-25 2014-12-17 阿勒根公司 将单链蛋白质细胞内转化成它们的双链形式的方法
SG10201506567UA (en) * 2010-05-20 2015-10-29 Allergan Inc Degradable Clostridial Toxins
AU2015261716B2 (en) * 2010-05-20 2018-01-04 Allergan, Inc. Degradable clostridial toxins
WO2012048246A1 (en) 2010-10-08 2012-04-12 Allergan, Inc. Reduction of antibody response against botulinum neurotoxin and variants thereof
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016094555A1 (en) 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
DK3242884T3 (da) 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
CA3127985A1 (en) 2019-02-04 2020-08-13 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
ATE200493T1 (de) * 1990-03-02 2001-04-15 Boston Medical Ct Corp Verbesserte chimäre toxine
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
EP0760681B1 (en) * 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DK0773788T3 (da) * 1995-06-06 2003-09-01 Allergan Inc Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
EP0909322B1 (en) * 1996-04-30 2005-11-16 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9618960D0 (en) * 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US6444209B1 (en) * 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
EP0941334B1 (en) * 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998029540A2 (de) * 1997-01-02 1998-07-09 B.R.A.I.N. Biotechnology Research And Information Network Gmbh REKOMBINANTE FUSIONSPROTEINE AUF DER BASIS RIBOSOMEN-INAKTIVIERENDER PROTEINE DER MISTEL $i(VISCUM ALBUM)
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) * 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
IL129427A0 (en) 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
EP2267010B1 (en) * 1999-08-25 2014-05-07 Allergan, Inc. Activatable recombinant neurotoxins
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6831059B2 (en) * 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
JP2008532549A (ja) * 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素

Also Published As

Publication number Publication date
AU2002228684B9 (en) 2007-03-22
EP1381677A2 (en) 2004-01-21
CA2430365A1 (en) 2002-06-06
US20070292920A1 (en) 2007-12-20
US20120135495A1 (en) 2012-05-31
AU2002228684B2 (en) 2007-01-25
WO2002044199A2 (en) 2002-06-06
US20020137886A1 (en) 2002-09-26
AU2868402A (en) 2002-06-11
WO2002044199A3 (en) 2003-11-06
US8309686B2 (en) 2012-11-13
US7456272B2 (en) 2008-11-25
JP2005506036A (ja) 2005-03-03
US7273722B2 (en) 2007-09-25

Similar Documents

Publication Publication Date Title
BR0115624A (pt) neurotoxinas com especificidade alvo melhorada
ATE553118T1 (de) Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz
MX2022012685A (es) Compuestos específicos contra la proteína s de coronavirus y usos de los mismos.
MXPA03000576A (es) Motivo a base de leucina y neurotoxinas clostridial.
BRPI0412265A (pt) uso de calcitonina em osteoartrite
ATE416191T1 (de) Abbaubare clostridientoxine
BRPI0407974A (pt) neurotoxinas clostridiais para tratar distúrbios uterinos
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
PT996468E (pt) Conjugados de lectinas que se ligam a galactose e neurotoxinas de clostridio como analgesicos
BR0114748A (pt) Sensor laser de fibra anisotrópica com acoplamento por reação distribuìda
ATE355520T1 (de) Kristallstruktur von bace und verwendungen dafür
ATE368436T1 (de) Zusammenpressender zusammengesetzter elastischer strumpf
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE370770T1 (de) Hautreinigungsmittel
BRPI0414370A (pt) enzimas modificadas, processos para produzir enzimas modificadas e usos das mesmas
BR0110999A (pt) Misturas de adesivos aquosos
BR0210543A (pt) Tablete macio de caldo de carne
NZ592736A (en) Acupuncture device including a needle rod to which an acupressure member is connected
BR0110969A (pt) Inibição de pepsina por alginatos
BRPI0501313A (pt) ferro de passar roupa que compreende uma base com formato particular
BR0210496A (pt) Caldo de carne em pó
BRPI0412243A (pt) uso de cd164 solúvel em distúrbios inflamatórios e/ou autoimunes
BR0111983A (pt) métodos e substratos de peptìdeo de metaloprotease
DE69732784D1 (de) Inhibierung von invasiver remodulierung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.